********************Clinician response to elevated Lp(a) is modest — implementation gap after guideline mandate********************
Key Questions
What is the typical clinician response to elevated Lp(a) levels?
Clinician follow-up for elevated Lp(a) is modest, with only 0.1% action in low-risk cases despite guideline mandates, indicating a significant implementation gap.
How does Lp(a) interact with coronary artery calcium (CAC) to affect ASCVD risk?
Lp(a) >50 mg/dL combined with CAC >0 triples ASCVD risk, presented at ACC.26, while CAC=0 predicts low events, aiding risk stratification.
What guidelines or regions advocate for Lp(a) testing?
India's LAI guideline recommends Lp(a) testing from age 18; universal testing reviews push harmonization with ESC guidelines for improved risk assessment.
What solutions are proposed to improve Lp(a) implementation?
Strategies include order-sets, EHR integration, and quality improvement initiatives, amid ongoing phase 3 trials for pelacarsen and olpasiran.
Is universal Lp(a) testing supported for risk stratification?
Yes, universal Lp(a) testing gains support for better risk stratification, with evidence reviews calling for guideline updates and CAC scoring to refine elevated Lp(a) risk.
Mar 2026: low 0.1% follow-up low-risk; Lp(a)/CAC ACC.26 synergy triples ASCVD risk if Lp(a)>50 + CAC>0 (low events if CAC=0). Cleveland Clinic awareness; India LAI gline age18; clinician narrative review; universal testing reviews push harmonization with ESC; fixes: order-sets/EHR/QI amid pelacarsen/olpasiran ph3.